BOC Sciences provides route of administration design services that help research teams match an API, its biopharmaceutical profile, and the intended delivery objective to a practical, developable administration route. Combining physicochemical characterization, formulation feasibility screening, permeability and release assessment, and pharmacokinetic analysis, we guide selection among oral, parenteral, pulmonary, nasal, oromucosal, dermal, transdermal, ocular, otic, rectal, vaginal, implantable, and depot routes. Each project is planned around the molecule's properties, target tissue, dose requirements, desired exposure profile, and dosage-form feasibility. Our approach integrates with broader formulation services to move a candidate from initial route assessment to a practical drug product development strategy.
The route of administration determines how quickly and completely a drug reaches its site of action, how convenient it is for the patient to use, and how realistic the downstream formulation and manufacturing steps become. A route selected too early, before the molecule's solubility, permeability, stability, and dose requirements are understood, often leads to reformulation delays, poor exposure, or a delivery system that patients find difficult to use.These constraints should be examined before extensive formulation work begins.
BOC Sciences designs oral formulations that improve bioavailability, control release, and support patient-friendly once-daily dosing for poorly soluble or highly variable APIs.
We design injectable formulations across intravenous, subcutaneous, intramuscular, and intrathecal routes, balancing stability, tonicity, viscosity, and injection comfort.
Our inhalation design services target the lung directly for local or systemic delivery, enabling rapid onset and reduced doses compared with oral or parenteral routes.
BOC Sciences develops nasal and oromucosal formulations that bypass first-pass metabolism and enable fast absorption or local action for systemic and topical indications.
We design topical and transdermal systems that deliver drug to the skin locally or systemically, improving adherence through non-invasive, sustained, and convenient administration.
BOC Sciences formulates ocular and otic products that maintain drug at the target tissue, extending retention and improving therapy for chronic eye and ear conditions.
Our rectal and vaginal formulation services provide alternatives for patients who cannot use oral therapy, enabling local treatment or partial systemic absorption.
We design long-acting local and depot systems that release drug over weeks or months, improving adherence and targeting the site of disease directly.
BOC Sciences helps research teams move from an API and a target exposure profile to a candidate route, a practical dosage form, and a delivery system backed by physicochemical, permeability, and release evidence.
BOC Sciences supports route selection across the full small-molecule and biologic development spectrum. Each scenario requires a different combination of profiling, feasibility, and exposure data. The table below summarizes the development scenarios we routinely support and the service scope we apply to each.
| Development Scenario | Route Selection Focus & Key Outputs |
| Early NCE Developability | Physicochemical and biopharmaceutical profiling to identify the most developable route, with candidate dosage form recommendations, early formulation feasibility data, and API analysis support. |
| Oral Bioavailability Enhancement | Salt, polymorph, solid dispersion, lipid, and nanosizing strategies to raise exposure for poorly soluble or poorly permeable APIs intended for oral dosing, supported by formulation design. |
| Parenteral Delivery of Biologics and Peptides | Injectable solution, suspension, and lyophilized formulation design with stability, viscosity, and high-concentration delivery assessment. |
| Non-Invasive Route Exploration | Comparative evaluation of transdermal, pulmonary, nasal, and oromucosal routes for peptides, hormones, and small molecules requiring an alternative to injection. |
| Local vs. Systemic Delivery Decisions | Assessment of ocular, otic, dermal, inhalation, rectal, and vaginal routes to decide whether local action or systemic exposure best meets the therapeutic goal. |
| Long-Acting and Depot Development | Implantable, microsphere, and in-situ depot design with release kinetics and burst control to support extended-duration dosing. |
| Route Switch and Reformulation | Life-cycle management to move a product from one route to a more convenient or more effective route, with full feasibility and stability studies support. |
| Patient-Centric Design | Selection of routes and dosage forms that improve ease of use, adherence, and convenience for the target patient population. |
Share your API structure, target indication, dose and exposure requirements, preferred route, current formulation problem, and any available PK data. Our specialists will design a project-specific plan covering physicochemical profiling, barrier and permeability assessment, formulation feasibility, and exposure prediction to help you select and de-risk the most practical administration route.
BOC Sciences reviews the target tissue, desired local or systemic exposure, onset, duration, dose, dosing frequency, candidate properties, current formulation, available data, and user-related constraints. We then define measurable route-selection criteria and identify the most plausible primary and backup routes.
Each candidate route is translated into a dosage-form concept with defined dose volume, concentration, release pattern, excipient functions, device needs, and performance attributes. A decision matrix highlights technical advantages, limitations, dependencies, material needs, and the experiments required to distinguish the leading options.
Our team prepares fit-for-purpose prototypes and compares solubility, stability, release, permeability, aerosolization, injectability, rheology, retention, or other route-relevant attributes. When needed, in vitro ADME, bioanalysis, and in vivo exposure studies connect formulation behavior with local or systemic delivery performance.
Clients receive methods, analytical results, prototype compositions, comparison tables, risk interpretation, and the rationale for the recommended route. The package also defines backup options, unresolved questions, critical formulation attributes, and a practical hand-off plan for continued development.
Low exposure can arise from incomplete release, poor dissolution, limited permeability, presystemic metabolism, rapid local clearance, or insufficient residence time. BOC Sciences uses a cause-based sequence rather than immediately changing the formulation. We compare mass balance, barrier transport, stability, and exposure data, then test focused interventions such as particle engineering, permeation enhancement, retention improvement, or a different dosage form. If the route remains impractical, the evidence supports a timely alternative-route decision.
A molecule may dissolve in a screening solvent yet precipitate after dilution, degrade at the route-relevant pH, or cross the target barrier too slowly for the required dose. BOC Sciences separates these liabilities through pH-solubility profiles, kinetic solubility, stability studies, permeability models, and prototype testing. We then compare pH adjustment, salt or solid-form options, co-solvents, surfactants, lipid systems, amorphous dispersions, and nanosuspension or microemulsion strategies according to route constraints.
A technically active formulation may still fail as a delivery concept when the dose requires too many tablets, excessive injection volume, high viscosity, long nebulization time, or a patch area beyond practical use. Our team calculates route-specific dose and concentration requirements early, then evaluates loading efficiency, rheology, aerosol output, injection force, device compatibility, and release rate. This exposes infeasible concepts before extensive optimization and helps define realistic formulation and device targets.
Local delivery should retain sufficient drug near the target while controlling unwanted systemic distribution, whereas systemic delivery must overcome local barriers without trapping the dose at the administration site. BOC Sciences compares release rate, tissue permeation, residence, absorption, and biodistribution to locate the limiting step. Formulation composition, particle size, mucoadhesion, depot behavior, and administration placement can then be adjusted to produce an exposure profile that better matches the project objective.
Collaborate with BOC Sciences to compare administration routes through integrated molecule profiling, dosage-form design, prototype screening, barrier assessment, bioanalysis, and exposure evaluation. Receive a clear recommendation supported by route-specific data and practical next steps.
BOC Sciences begins with the molecule's physicochemical and biopharmaceutical reality rather than a preferred dosage form. We profile solubility, permeability, stability, and dose requirements before recommending a route, so the final selection is grounded in data and more likely to survive downstream development.
Our route design combines formulation development, barrier and permeability assessment, release testing, and exposure evaluation in a single coordinated workflow. This integration reduces fragmented project execution and gives clients coherent evidence for route and dosage form decisions.
From formulation design and screening to oral, injectable, inhalation, transdermal, nasal, ocular, and depot systems, BOC Sciences covers a wide range of routes and dosage forms. This breadth lets us compare options fairly and select the most practical route for the molecule.
We weigh efficacy, safety, manufacturability, and patient experience together when selecting a route. Our recommendations favor routes and dosage forms that are convenient to use and realistic to produce, improving adherence and increasing the chance of successful commercial outcomes.
Client Needs: A discovery team had a BCS class II NCE with an aqueous solubility below 5 μg/mL at physiological pH and needed a practical oral route for once-daily dosing of a 50 mg target dose. Their early prototype showed low and variable exposure, and they asked for a route and formulation strategy that could be carried into early development.
Challenges: The compound was poorly soluble, exhibited pH-dependent dissolution, and showed significant first-pass loss. A conventional immediate-release tablet could not provide the required exposure, and the team needed evidence to decide whether oral delivery was feasible at all or whether a parenteral route would be required.
Solution: We profiled solubility across the gastrointestinal pH range, screened salt, amorphous solid dispersion, and nanosizing approaches, and tested formulations in dissolution and simulated intestinal conditions. We then used PK analysis to compare exposure from the lead amorphous solid dispersion against the crystalline form across 18 formulation and dose-ratio combinations, selecting a design that raised projected bioavailability with an acceptable dose volume.
Outcome: The client received an oral solid dose strategy supported by solubility, dissolution, and comparative exposure data, enabling them to progress the NCE with confidence in the selected route.
Client Needs: A biologics team working on a short-acting peptide wanted to compare subcutaneous injection with a pulmonary route for a systemic indication, aiming to improve patient convenience without losing exposure. They needed route-specific formulation feasibility and comparative data to support their decision.
Challenges: The peptide was susceptible to enzymatic degradation in the gastrointestinal tract, ruling out oral delivery. Subcutaneous injection required high-concentration formulation with careful viscosity and stability control, while the pulmonary route required aerosol particle engineering to reach the deep lung and achieve systemic absorption.
Solution: We developed a high-concentration subcutaneous solution and a dry-powder inhalation candidate in parallel, assessing stability, viscosity, and aerodynamic particle size for the inhaled form. Comparative exposure modeling across both routes, supported by particle size distribution and release testing, showed the pulmonary route could achieve rapid absorption with a lower dose, while the subcutaneous route offered more reproducible exposure. We delivered a route comparison package with formulation feasibility data for both options.
Outcome: The client selected the subcutaneous route for the lead program and retained the pulmonary data for a follow-on product, with clear evidence supporting both decisions.
The best route is selected by matching the required site and pattern of exposure with the molecule's physicochemical and biopharmaceutical properties. Key factors include dose, solubility, permeability, pKa, lipophilicity, molecular size, stability, metabolism, desired onset and duration, local versus systemic delivery, dosage-form feasibility, administration volume, and device requirements. No route is optimal for every candidate. A sound decision compares several plausible routes, identifies the barrier most likely to limit each option, and uses targeted formulation, release, permeability, and pharmacokinetic studies to rank them.
The administration route affects how quickly and completely a drug reaches its target site or systemic circulation. Intravenous delivery enters the circulation directly, while oral delivery depends on release, dissolution, gastrointestinal stability, intestinal permeability, and first-pass metabolism. Nasal, pulmonary, oromucosal, and transdermal routes may avoid some gastrointestinal limitations, but they introduce other constraints involving clearance, tissue barriers, retention, release rate, and dose capacity. Route comparisons should therefore consider absorption rate, peak exposure, tissue distribution, local retention, and exposure duration rather than relying only on total systemic bioavailability.
Low aqueous solubility, slow dissolution, limited membrane permeability, large molecular size, enzymatic degradation, and unsuitable lipophilicity can restrict oral or other non-invasive delivery. A high dose may also create problems involving tablet burden, spray volume, patch area, or mucosal absorption capacity. Peptides, proteins, and oligonucleotides introduce additional challenges such as aggregation, proteolysis, mucus trapping, and inefficient cellular uptake. Formulation technologies can address some of these limitations, but solubility, stability, release, and permeability testing should first identify the dominant barrier and determine whether the proposed route remains technically feasible.
Useful starting information includes the candidate structure or sequence, molecular weight, pKa, logP or logD, solubility, stability, solid-state properties, expected dose, target tissue, local or systemic delivery objective, and desired onset and duration. Available formulation, ADME, and pharmacokinetic data should also be shared, together with the preferred route, acceptable alternatives, sample availability, known development problems, and dosage-form or device constraints. When the data package is incomplete, BOC Sciences can begin with a gap assessment and define the prediction, characterization, and feasibility experiments that should be prioritized.
Yes. BOC Sciences can compare oral, parenteral, pulmonary, nasal, oromucosal, transdermal, ocular, otic, rectal, vaginal, implantable, and depot routes within one structured project. The comparison may cover molecular suitability, dose and concentration requirements, dosage-form and device feasibility, release, permeability, stability, local retention, tissue distribution, and pharmacokinetic performance. Project outputs can include a route comparison matrix, critical risks, prototype formulation data, a recommended primary route, technically credible alternatives, and a focused testing plan for continued development, giving research teams a clear basis for route selection.
BOC Sciences provided a structured comparison of oral, parenteral, and non-invasive routes for our candidate. The route assessment helped us understand which options were realistic for our molecule and reduced uncertainty about the development path.
— Dr. McCarthy, Formulation Scientist, Early Development
The feasibility work gave us clear, actionable guidance on dosage form selection. BOC Sciences explained which formulation strategies were most likely to work for our poorly soluble compound and helped us move forward without repeated trial and error.
— Ellison, Project Manager, Drug Product Development
The final data package was complete and easy to review, with solubility, permeability, release, and exposure results presented together. It gave our leadership team the evidence needed to support the selected administration route with confidence.
— Dr. Okoro, Head of Formulation, Biologics R&D
The team kept us updated at each stage and responded quickly to our technical questions. The collaborative approach made the route selection process smooth and gave us confidence in the recommendations provided.
— Coleman, Senior Research Manager, Drug Delivery
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
